Clinical Trials
26 trialsNCT06898970 2026-05-08
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
University of California, San Francisco
Phase 2 Active not recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT04668300 2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT01303497 2026-03-13
ANGIO-TAX+
Centre Oscar Lambret
Phase 2 Completed
NCT06849986 2026-01-08
TAIS
Fudan University
Phase 2 Recruiting
NCT03331250 2025-12-23
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05026736 2025-08-17
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02815995 2025-06-12
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04873375 2024-10-31
Cemiplimab for Secondary Angiosarcomas
Radboud University Medical Center
Phase 2 Completed
NCT04518124 2023-11-22
Propranolol in Angiosarcoma
The Netherlands Cancer Institute
Phase 2 Completed
NCT02584309 2023-11-07
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Phase 2 Completed
NCT05961761 2023-07-27
PROPANE
Herlev and Gentofte Hospital
Phase 2 Recruiting
NCT03921073 2022-11-01
Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01462630 2022-08-19
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Fox Chase Cancer Center
Phase 2 Completed
NCT02048722 2022-04-25
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Northwestern University
Phase 2 Completed
NCT02212015 2022-03-22
EVA
Heidelberg University
Phase 2 Terminated
NCT05116800 2021-12-07
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Phase 2 Withdrawn
NCT01532687 2021-09-27
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT04906876 2021-07-28
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
Phase 2 Withdrawn
NCT03512834 2018-07-11
ASAP
Dong-A University Hospital
Phase 2 Unknown
NCT00288015 2018-06-25
Bevacizumab in Treating Patients With Angiosarcoma
Northwestern University
Phase 2 Completed
NCT01055028 2018-03-26
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Stanford University
Phase 2 Terminated
NCT00217607 2016-08-30
Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery
UNICANCER
Phase 2 Completed
NCT00887809 2016-01-25
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00474994 2016-01-20
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 2 Completed